Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III
Status:
Unknown status
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The use of induction chemotherapy is feasible and effective. It is also logistically
beneficial for decreasing micrometastases and radiation-related toxicity by decreasing tumor
burden before definite locoregional concurrent therapy. Previously the investigators
conducted several phase II study of IP chemotherapy in advanced NSCLC and demonstrated that
IP chemotherapy has a promising activity and readily manageable toxicity profile. Given the
encouraging activity of IP chemotherapy in the advanced stage setting, the investigators
postulated that their further investigation in the stage III setting might lead to further
prolongation of survival times. In addition to cisplatin, Irinotecan has been demonstrated to
act as radiation sensitizers in preclinical and clinical setting. Therefore, their use with
concurrent radiotherapy might lead to radiation sensitization and improved locoregional
control.